Skip to main content

Table 1 Poisson regression analysis assessing the relationship between Euro-GASP versus national antimicrobial susceptibility data to azithromycin, cefixime and ciprofloxaxin by country and overall, 2009 to 2013

From: The European gonococcal antimicrobial surveillance programme (Euro-GASP) appropriately reflects the antimicrobial resistance situation for Neisseria gonorrhoeae in the European Union/European Economic Area

 

Azithromycin

Cefixime

Ciprofloxacin

Source b

Country

IRR

P value

CI-lower

CI-upper

No. of tests/years

IRR

P value

CI-lower

CI-upper

No. of tests/years

IRR

P value

CI-lower

CI-upper

No. of tests/years

Austria

0.138

< 0.0001

0.085

0.224

3456/4

0.052

< 0.0001

0.03

0.089

3454/4

1.000

0.995

0.885

1.129

3456/4

1

Belgium

0.68

0.079

0.442

1.046

3198/5

0.065

< 0.0001

0.18

0.241

1919/3

0.973

0.659

0.863

1.098

3198/5

1

Denmark

No national azithromycin susceptibility data available

No national cefixime susceptibility data available

1.006

0.923

0.895

1.131

2811/5

1

France

No national azithromycin susceptibility data available

0.871

0.747

0.375

2.019

5626/4

0.913

0.251

0.781

1.067

5628/4

2

Germany

6.085

0.083

0.791

46.79

321/1

Model not performed - too few positive isolates

1.447

0.018

1.064

1.968

321/1

2

Greece

1.078

0.781

0.634

1.832

425/3

1.282

0.415

0.705

2.331

505/3

1.008

0.917

0.87

1.167

1053/5

1

Hungary

Model not performed - too few positive isolates

Model not performed - too few positive isolates

0.98

0.839

0.803

1.194

776/3

2

Italy

0.944

0.794

0.615

1.451

1144/4

0.863

0.537

0.539

1.38

1170/4

1.003

0.972

0.859

1.171

1134/4

1

Malta

No resistant isolates

  

No national cefixime susceptibility data available

1.004

0.983

0.708

1.424

219/4

1

The Netherlands

2.23

0.003

1.324

3.757

4440/3

No national cefixime susceptibility data available

1.097

0.133

0.972

1.237

7695/5

2

Norway

1.389

0.152

0.886

2.177

594/2

2.22

0.037

1.051

4.687

594/2

1.063

0.596

0.848

1.334

594/2

1

Slovakia

No national azithromycin susceptibility data available

0.921

0.883

0.309

2.748

325/1

1.112

0.527

0.801

1.544

325/1

1

Slovenia

1.434

0.287

0.739

2.781

377/5

1.219

0.527

0.66

2.253

377/5

0.987

0.92

0.762

1.277

377/5

1

Sweden

1.818

0.002

1.252

2.638

4158/5

2.005

0.006

1.225

3.281

4158/5

0.956

0.459

0.849

1.077

4158/5

1

The United Kingdom

0.83

0.554

0.448

1.538

8154/5

1.706

0.042

1.02

2.852

8154/5

1.013

0.825

0.903

1.136

8154/5

1

All countries - univariate

 Systema

1.09

0.269

0.935

1.271

26,267

0.863

0.101

0.724

1.029

26,282

1.008

0.697

0.969

1.049

39,889

 

 Sourceb

0.98

0.977

0.227

4.217

26,267

0.248

0.121

0.043

1.443

26,282

0.838

0.209

0.637

1.104

39,889

 
  1. aSystem = Euro-GASP data (1) vs. national data (2)
  2. bSource = Source of comparison data; all data from Euro-GASP laboratory (1) vs. part or no data from Euro-GASP laboratory (2)
  3. IRR incidence-rate ratio, CI 95% confidence interval. Significant values (< 0.05) in bold
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us